THE "NEW" PROSTATE CANCER INFOLINK

Pages

• Ask Questions
  • Ask Arnon … he’s a prostate cancer surgeon
  • Ask Arthur … pretty much anything you like
  • Ask Amy … to Get a Woman’s Point of View
• Risk + Prevention
  • Are you taking Propecia (finasteride) for hair loss?
  • Finding cancer in a man’s prostate is NORMAL!
  • Projection of prostate cancer risk in Europe
  • The importance of exercise and wellness
  • The PCPT prostate cancer risk calulator
  • The Sunnybrook prostate cancer risk calculator
  • What is prostate cancer?
  • Who is at risk for prostate cancer?
    • Genetics and prostate cancer risk
    • Age and prostate cancer risk
    • Race and prostate cancer risk
    • Diet and the environment
    • Does having a vasectomy cause prostate cancer?
  • Prevention: an introduction
    • Dutasteride and the REDUCE trial
    • Is extract of pomegranate an elixir of life?
    • Preventing prostate cancer (a video presentation)
    • The Physicians Health Study II randomized controlled trial
    • The prevention of prostate cancer with 5α-reductase inhibitors (5-ARIs)
    • Are all cases of prostate cancer equal in risk?
    • Finasteride and the Prostate Cancer Prevention Trial (PCPT)
    • Selenium, vitamin E, and the SELECT trial
    • The toremifene/PIN trial
  • Prostate specific antigen (PSA) as a long-term marker of risk for prostate cancer
• Diagnosis
  • For newly diagnosed patients …
  • WELCOME to The “New” Prostate Cancer InfoLink!
  • Prostate cancer screening and early detection
    • Prostate cancer screening — should you or shouldn’t you? (a video presentation)
    • Prostate cancer screening and the ERSPC trial
    • The role of PSA today (in prostate cancer diagnosis)
      • How your DRE and PSA results affect whether you need a prostate biopsy: a video presentation
    • Is regular prostate cancer testing appropriate for everyone?
    • Prostate cancer screening and the PLCO trial
    • The Tyrol, Austria and King County, Washington screening studies
    • For men over 75: The Iowa Prostate Cancer Consensus
  • Signs and symptoms of prostate cancer
  • The digital rectal examination or DRE
    • What to expect from a prostate exam (a video presentation)
  • Prostate specific antigen testing
    • Different PSA tests and how they can be used
    • PSA velocity: is it important to prostate cancer risk
  • Diagnosis: an introduction
  • Prostate biopsy: how it’s done and what’s involved
    • Prostate biopsy: when you may need one and what to expect (two video presentations)
  • What on Earth is PIN?
  • That’s not what ASAP stands for! Is it?
  • Other important tests in the diagnosis of prostate cancer
    • The prostatic acid phosphatase or PAP test
    • MRI, CT, and other imaging tests in diagnosis of prostate cancer
    • Bone scans in diagnosis of prostate cancer
• Management
  • The natural history of conservatively treated prostate cancer
  • In the beginning …
  • Staging and grading
    • Overview of grading and staging for prostate cancer: a video presentation
    • Clinical staging
      • The stages of prostate cancer: a video presentation
    • Pathological staging
    • Understanding Gleason grading
      • Understanding your tumor grade: a video presentation
      • Gleason grades 1 and 2
      • Gleason grade 3
      • Gleason grade 4
      • Gleason grade 5
    • The Gleason score and what it means
    • Misstaging and misgrading: it’s a problem
  • Treatment: the absolute basics
  • First-line treatments for early stage (localized) prostate cancer
    • Cryotherapy in treatment of early stage (localized) prostate cancer
    • The “Quality of Life and Satisfaction with Outcomes” study
    • What! You mean I’m going to have to CHOOSE?
    • Comparative data on the various options for treatment of early stage (localized) prostate cancer
      • Watchful waiting vs. radical surgery: the Scandinavian trial
      • LRP vs. RRP: the Memorial Sloan-Kettering data
    • Active surveillance and watchful waiting in management of early stage (localized) prostate cancer
      • Active surveillance in management of localized disease: a video presentation
      • The downsides of conservative management
      • Watchful waiting for localized disease: a video presentation
    • Established surgical treatments for early stage (localized) prostate cancer
      • Radical prostatectomy: a brief historical note
      • Open radical retropubic prostatectomy (RRP) for treatment of early stage (localized) prostate cancer
      • Open radical perineal prostatectomy (RPP) for treatment of early stage (localized) prostate cancer
      • Minimally invasive (laparoscopic) radical prostatectomy (LRP) for treatment of early stage (localized) prostate cancer
        • Who needs a robot — and why?
    • Established radiotherapeutic treatments for early stage (localized) prostate cancer
    • Other forms of treatment for early stage (localized) prostate cancer
      • High-intensity focused ultrasound (HIFU) in treatment of early stage (localized) prostate cancer
    • Focal therapy for localized prostate cancer: a future possibility?
  • When first-line treatment fails the patient with early stage disease
    • Establishing risk and prognosis in men with biochemical recurrence after first-line therapy for early stage disease
    • Expectant management of men with biochemical recurrence after first-line therapy for early stage disease
    • Investigational forms of salvage therapy for patients in biochemical relapse after first-line treatment for early stage disease
    • The role of salvage radiation therapy after failure of first-line treatment for early stage prostate cancer
    • The role of salvage surgery after failure of non-surgical first-line treatment for early stage prostate cancer
    • The role(s) of hormone therapy in treatment of patients with biochemical recurrence after first-line treatment for early stage disease
  • The treatment of metastatic prostate cancer
    • The treatment of metastatic prostate cancer: a video presentation
    • Orchiectomy in treatment of metastatic prostate cancer
    • The luteinizing hormone releasing hormone (LHRH) agonists in treatment of metastatic prostate cancer
    • The luteinizing hormone releasing hormone (LHRH) antagonists in treatment of metastatic prostate cancer
    • Nonsteroidal antiandrogens in treatment of metastatic prostate cancer
  • The treatment of hormone-refractory prostate cancer
    • Bone loss after androgen deprivation for prostate cancer
  • Exercise, wellness, and response to prostate cancer treatment
  • Living with prostate cancer
    • Introduction to integrative oncology
  • Important articles on the management of prostate cancer
• Tips + Tools
  • Finding the medical oncologist who is right for you: one specialist’s opinion
  • Nine tips for picking a radiation oncologist to treat your prostate cancer
  • Prostate cancer-related abbreviations
  • What cancer cannot do
  • The “top 10″ facts you need to know
  • Views from the “other side”
  • Major US-based prostate cancer web sites and organizations
  • Finding the prostate cancer specialist who is right for YOU
  • Major ex-US prostate cancer-related web sites and organizations
  • How to pick a prostate cancer surgeon
  • How to select your brachytherapist
  • The Partin tables and how to use them
    • Predicting your prostate cancer tumor stage: a video presentation
  • The Han tables and how to use them
  • The Kattan nomograms and how to use them
  • Other prognostic tables and nomograms
  • Finding out about clinical trials
    • Important things you need to know about clinical trials
    • How to use ClinicalTrials.gov
    • The Nexcura database
    • The CenterWatch clinical trials listing service
• Site Map
  • “Clergy of the World Unite”
  • Prostate cancer educational events for patients
  • Prostate cancer in Kenya: an introduction
  • About Us / Newsroom
    • How is this service financed?
    • Polls and surveys
    • Some background on The “New” Prostate Cancer InfoLink
    • The Scientific Advisory Board to The “New” Prostate Cancer InfoLink
    • Management and other personnel
    • Media commentary on and articles about The “New” Prostate Cancer InfoLink
    • For the media: who to contact, and how
    • Electronic media kit and related materials
    • Media releases
      • Media release: Sunday, August 17, 2008
      • Media release: Sunday, July 27, 2008
  • Copyright
  • What’s on this site (and how to use it)
  • Prostate cancer awareness … issues and events